m6A-centered Drug Response Information

General Information of the Drug (ID: M6ADRUG0041)
Name
Artenimol
Synonyms
Dihydroartemisinin; Artenimol; Dihydroqinghaosu; UNII-6A9O50735X; 81496-82-4; (3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano[4,3-j][1,2]benzodioxepin-10-ol; GNF-PF-5634; 6A9O50735X; b-Dihydroartemisinin; GTPL9957; SCHEMBL17156483; CHEBI:135921; HY-N0176; ZINC15449187; AKOS032949625; CS-5595; FT-0649320; BRD-K62213621-001-01-6; Dihydroartemisinin (mixture of alfa and beta isomers); (3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-ol
    Click to Show/Hide
Status Approved [1]
Structure
Formula
C15H24O5
InChI
InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12+,13-,14-,15-/m1/s1
InChIKey
BJDCWCLMFKKGEE-ISOSDAIHSA-N
PubChem CID
3000518
DrugBank ID
DB11638
Full List of m6A Targets Related to This Drug
Metastasis associated lung adenocarcinoma transcript 1 (MALAT1)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene [2]
Response Summary Renal fibrosis is a key factor in chronic kidney disease (CKD). Metastasis associated lung adenocarcinoma transcript 1 (MALAT1)/miR-145/FAK pathway was involved in the effect of dihydroartemisinin (DHA) on TGF-beta1-induced renal fibrosis in vitro and in vivo.
Responsed Disease Chronic kidney disease ICD-11: GB61
 Disease Info 
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Cell Process Epithelial-mesenchymal transition
In-vitro Model HK-2 [Human kidney] Normal Homo sapiens CVCL_0302
HK2 Normal Acipenser baerii CVCL_YE28
In-vivo Model For the unilateral ureteral obstruction (UUO) model, male C57BL/6J mice at 8 weeks of age (20-22 g body weight) were first anaesthetized with pentobarbital sodium (50 mg/kg) via intraperitoneal injection. Then, the left ureter was ligated using 3-0 silk and a left lateral incision.
References
Ref 1 Anti-malarial drug dihydroartemisinin downregulates the expression levels of CDK1 and CCNB1 in liver cancer. Oncol Lett. 2021 Sep;22(3):653. doi: 10.3892/ol.2021.12914. Epub 2021 Jul 9.
Ref 2 m(6)A-induced lncRNA MALAT1 aggravates renal fibrogenesis in obstructive nephropathy through the miR-145/FAK pathway. Aging (Albany NY). 2020 Mar 23;12(6):5280-5299. doi: 10.18632/aging.102950. Epub 2020 Mar 23.